Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Schlomm

Showing results (181-190 of 359) with videos related to

Pageof 36
Sort By:
European Urology|April 24, 2007
Marked gene transcript level alterations occur early during radical prostatectomyThorsten Schlomm, Esther Näkel, Andreas Lübke, et al.
International Journal of Oncology|January 28, 2015
Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancerMartina Kluth, Rami Galal, Antje Krohn, et al.
Molecular Cancer|November 23, 2013
High mitochondria content is associated with prostate cancer disease progressionKatharina Grupp, Karolina Jedrzejewska, Maria Christina Tsourlakis, et al.
Plos One|February 25, 2011
Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platformRamesh Ummanni, Frederike Mundt, Heike Pospisil, et al.
European Urology|January 18, 2006
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Thierry Lebeau, et al.
Journal of Endourology|March 22, 2008
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sumPierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, et al.
The Prostate|May 3, 2014
NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancerKatharina Grupp, Daniel Ospina-Klinck, Maria Christina Tsourlakis, et al.
European Urology|October 30, 2007
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliterSascha A Ahyai, Markus Graefen, Thomas Steuber, et al.
Molecular Oncology|August 15, 2013
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancersKatharina Grupp, Stella Sanader, Hüseyin Sirma, et al.
The Journal of Urology|September 9, 2014
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomyUwe Michl, Frederike Molfenter, Markus Graefen, et al.
Pageof 36

Showing results (181-190 of 359) with videos related to

Sort By:
Pageof 36
European Urology|April 24, 2007
Marked gene transcript level alterations occur early during radical prostatectomyThorsten Schlomm, Esther Näkel, Andreas Lübke, et al.
International Journal of Oncology|January 28, 2015
Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancerMartina Kluth, Rami Galal, Antje Krohn, et al.
Molecular Cancer|November 23, 2013
High mitochondria content is associated with prostate cancer disease progressionKatharina Grupp, Karolina Jedrzejewska, Maria Christina Tsourlakis, et al.
Plos One|February 25, 2011
Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platformRamesh Ummanni, Frederike Mundt, Heike Pospisil, et al.
European Urology|January 18, 2006
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Thierry Lebeau, et al.
Journal of Endourology|March 22, 2008
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sumPierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, et al.
The Prostate|May 3, 2014
NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancerKatharina Grupp, Daniel Ospina-Klinck, Maria Christina Tsourlakis, et al.
European Urology|October 30, 2007
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliterSascha A Ahyai, Markus Graefen, Thomas Steuber, et al.
Molecular Oncology|August 15, 2013
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancersKatharina Grupp, Stella Sanader, Hüseyin Sirma, et al.
The Journal of Urology|September 9, 2014
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomyUwe Michl, Frederike Molfenter, Markus Graefen, et al.
Pageof 36